Eden Healthcare Solutions

edenhcs.com.au

At Eden Healthcare Solutions, we specialize in providing equipment to hospitals, special schools and aged care facilities. We also have a showroom open to the public and a wide range of equipment designed to help elderly people remain independent in their own homes. We value honest, open, two-way communication, working to build long-term relationships with a deep understanding of our client’s needs.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharma Tech

LEO PHARMA AND VEEVA SYSTEMS PARTNER FOR DIGITAL PATIENT-CENTERED TRIALS

LEO Pharma | September 30, 2021

news image

LEO Pharma , a global leader in medical dermatology, and Veeva Systems announced a strategic technology partnership to enable scalable digital trials, paperless and patient-centered. Building on its success with the Veeva Clinical Operations suite, LEO Pharma will complete its standardization on existing Veeva clinical technology, be an early adopter of future Veeva solutions, and help shape the Veeva digital trials roadmap. By adopting technology and optimized business processes,...

Read More

Pharmacy Market

ASTRAZENECA AND R-PHARM SIGN AN AGREEMENT TO COOPERATE ON COVID-19 VACCINE DEVELOPMENT

AstraZeneca | December 22, 2020

news image

The Russian Direct Investment Fund (RDIF, Russia's sovereign abundance reserve), The Gamaleya National Center, AstraZeneca and R-Pharm have consented to an arrangement focused on the turn of events and usage of a clinical exploration program to survey the immunogenicity and security of the consolidated utilization of one of the segments of the Sputnik V immunization created by the Gamaleya Center, and one of the segments of the AZD1222 antibody, created by AstraZeneca and the University of O...

Read More

KIMERA® LABS FILES FIRST FDA INVESTIGATIONAL NEW DRUG (IND) APPLICATION USING XOGLO® FOR TREATMENT OF ARDS SECONDARY TO COVID-19

Prnewswire | August 18, 2020

news image

Kimera® Labs Inc, a privately held clinical stage biotechnology company, announces the filing of an extended FDA Investigational New Drug (IND) application to study the treatment of COVID-19 related inflammatory disease using Kimera's first-in-class XoGlo® isolated placental mesenchymal stem cell-based exosomes. Founded in 2012, Kimera® generated the first publicly available isolated exosome product and has treated over 35,000 thousand patients for a variety of investigatio...

Read More

Practice Management

ASTRAZENECA'S FARXIGA SCORES A SPEEDY FDA REVIEW IN KIDNEY DISEASE—AND GETS ANOTHER JUMP ON RIVAL JARDIANCE

Farxiga | January 07, 2021

news image

Pushing for another endorsement for SGLT2 prescription Farxiga in persistent kidney illness (CKD), AstraZeneca a year ago posted amazing information in its critical preliminary. Presently, the FDA has acknowledged its CKD application and granted a need survey, setting up a choice for the subsequent quarter—and putting Farxiga significantly farther in front of its future adversaries. In that preliminary, named Dapa-CKD, AZ's Farxiga in addition to standard of care cut the...

Read More
news image

Pharma Tech

LEO PHARMA AND VEEVA SYSTEMS PARTNER FOR DIGITAL PATIENT-CENTERED TRIALS

LEO Pharma | September 30, 2021

LEO Pharma , a global leader in medical dermatology, and Veeva Systems announced a strategic technology partnership to enable scalable digital trials, paperless and patient-centered. Building on its success with the Veeva Clinical Operations suite, LEO Pharma will complete its standardization on existing Veeva clinical technology, be an early adopter of future Veeva solutions, and help shape the Veeva digital trials roadmap. By adopting technology and optimized business processes,...

Read More
news image

Pharmacy Market

ASTRAZENECA AND R-PHARM SIGN AN AGREEMENT TO COOPERATE ON COVID-19 VACCINE DEVELOPMENT

AstraZeneca | December 22, 2020

The Russian Direct Investment Fund (RDIF, Russia's sovereign abundance reserve), The Gamaleya National Center, AstraZeneca and R-Pharm have consented to an arrangement focused on the turn of events and usage of a clinical exploration program to survey the immunogenicity and security of the consolidated utilization of one of the segments of the Sputnik V immunization created by the Gamaleya Center, and one of the segments of the AZD1222 antibody, created by AstraZeneca and the University of O...

Read More
news image

KIMERA® LABS FILES FIRST FDA INVESTIGATIONAL NEW DRUG (IND) APPLICATION USING XOGLO® FOR TREATMENT OF ARDS SECONDARY TO COVID-19

Prnewswire | August 18, 2020

Kimera® Labs Inc, a privately held clinical stage biotechnology company, announces the filing of an extended FDA Investigational New Drug (IND) application to study the treatment of COVID-19 related inflammatory disease using Kimera's first-in-class XoGlo® isolated placental mesenchymal stem cell-based exosomes. Founded in 2012, Kimera® generated the first publicly available isolated exosome product and has treated over 35,000 thousand patients for a variety of investigatio...

Read More
news image

Practice Management

ASTRAZENECA'S FARXIGA SCORES A SPEEDY FDA REVIEW IN KIDNEY DISEASE—AND GETS ANOTHER JUMP ON RIVAL JARDIANCE

Farxiga | January 07, 2021

Pushing for another endorsement for SGLT2 prescription Farxiga in persistent kidney illness (CKD), AstraZeneca a year ago posted amazing information in its critical preliminary. Presently, the FDA has acknowledged its CKD application and granted a need survey, setting up a choice for the subsequent quarter—and putting Farxiga significantly farther in front of its future adversaries. In that preliminary, named Dapa-CKD, AZ's Farxiga in addition to standard of care cut the...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us